J 2024

Metabolic Syndrome Prevalence in Women with Gestational Diabetes Mellitus in the Second Trimester of Gravidity

BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Veronika ŤÁPALOVÁ, Jan MÁCHAL et. al.

Basic information

Original name

Metabolic Syndrome Prevalence in Women with Gestational Diabetes Mellitus in the Second Trimester of Gravidity

Authors

BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Veronika ŤÁPALOVÁ, Jan MÁCHAL, Petr JANKŮ and Kateřina KAŇKOVÁ

Edition

JOURNAL OF CLINICAL MEDICINE, SWITZERLAND, MDPI, 2024, 2077-0383

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

Switzerland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.3390/jcm13051260(registeringDOI)

UT WoS

999

EID Scopus

999

Keywords in English

gestational diabetes; metabolic syndrome; pregnancy; obesity

Links

LX22NPO5104, research and development project.
Changed: 19/4/2024 03:52, RNDr. Daniel Jakubík

Abstract

V originále

Background: Women with gestational diabetes (GDM) have an increased risk of metabolic syndrome (MS) after delivery. MS could precede gravidity. The aims of this study were (i) to detect the prevalence of MS in women at the time of GDM diagnosis, (ii) to detect the prevalence of MS in the subgroup of GDM patients with any form of impaired glucose tolerance after delivery (PGI), and (iii) to determine whether GDM women with MS have a higher risk of peripartal adverse outcomes. Methods: A cross-sectional observational study comprised n = 455 women with GDM. International Diabetes Federation (IDF) criteria for MS definition were modified to the pregnancy situation. Results: MS was detected in 22.6% of GDM patients in those with PGI 40%. The presence of MS in GDM patients was associated with two peripartal outcomes: higher incidence of pathologic Apgar score and macrosomia (p = 0.01 resp. p = 0.0004, chi-square). Conclusions: The presence of MS in GDM patients is a statistically significant risk factor (p = 0.04 chi-square) for PGI. A strong clinical implication of our findings might be to include MS diagnostics within GDM screening using modified MS criteria in the second trimester of pregnancy.
Displayed: 18/6/2025 17:29